169 results
Page 4 of 9
8-K
EX-99.1
gje5ny2
20 Nov 20
Regulation FD Disclosure
7:36am
8-K
EX-99.1
jblbmypjwu39ag9yld
19 Nov 20
Durable Responses with ADP-A2M4 in Synovial Sarcoma with Confirmed Responses in 44% of Patients and Disease Control Rate of 94% Presented at CTOS
9:09am
8-K
EX-99.1
a3bnufwq1bku8fidyu
9 Nov 20
Two Confirmed Responses and Five out of Six Patients with Initial Tumor Reductions from Early Dose Cohorts of SURPASS Trial, Presented at SITC
5:11pm
8-K
EX-99.1
wge1xh
5 Nov 20
Adaptimmune Reports Q3 Financial Results and Business Update
7:40am
8-K
EX-99.1
6o1t4hq52s35oie9s73f
15 Oct 20
Adaptimmune Provides Full Contents of its SITC Abstract for the Phase 1 SURPASS Trial
4:47pm
8-K
EX-99.1
u6zbnz2iyg1q6tbocir0
28 Aug 20
Regulation FD Disclosure
10:44am
S-3ASR
EX-1.2
mu8qf0kiq5t
10 Aug 20
Automatic shelf registration
5:01pm
8-K
EX-99.1
dwfakieccdbi
6 Aug 20
Adaptimmune Reports Q2 Financial Results and Business Update
7:37am
8-K
EX-99.1
8vjj567em
2 Jun 20
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
4:49pm
8-K
EX-99.2
ygl oq9nk
2 Jun 20
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
4:49pm
8-K
EX-1.1
6wu4w9o26yc
2 Jun 20
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
4:49pm
8-K
EX-99.1
jfeoyiw260dpzv22ol3
29 May 20
Regulation FD Disclosure
7:42am
8-K
EX-99.1
qpbceln6k
14 May 20
Adaptimmune Reports Q1 Financial Results
7:37am
8-K
EX-99.1
ak6048 bwyvd
12 May 20
SPEAR T-cells Derived from Stem-Cells Kill Cancer Targets - Adaptimmune Presents Advances from its Allogeneic Platform at ASGCT Annual Meeting
10:54am
8-K
st8rov pohw24v
29 Apr 20
Other Events
8:06am
8-K
EX-99.1
xix3n74x
29 Apr 20
Other Events
8:06am
8-K
EX-99.1
qdt8gn7chwhng5o
28 Apr 20
Other Events
8:26am